BioSpace
273 episodes — Page 1 of 6
Beyond equity: Why venture debt is reshaping European biotech
Oct 8, 202622 min
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
Oct 7, 202624 min
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
Oct 1, 202620 min
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Sep 30, 202620 min
How radioligand therapy is rewriting cancer care
Sep 24, 202615 min
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
Sep 23, 202621 min
When vision fades: Rethinking wet AMD and the durability gap
Sep 17, 202621 min
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
Sep 16, 202622 min
The supply chain fault lines of modern pharma
Sep 10, 202636 min
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
Sep 9, 202620 min
Breaking borders: Building biotech scale in Benelux
Sep 3, 202618 min
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
Sep 2, 202620 min
Fragile X at a turning point: Breaking through the clinical bottleneck
Aug 27, 202619 min
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Aug 26, 202623 min
Rewriting the rules of CMV prevention
Aug 20, 202619 min
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
Aug 19, 202619 min
The Italian inflection point: Clinical strength, culture and capital
Aug 13, 202618 min
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
Aug 12, 202619 min
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
Aug 11, 202623 min
The next treatment-resistant depression paradigm
Aug 6, 202620 min
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
Aug 5, 202624 min
Life after the lead asset: Advancing an early-stage pipeline
Jul 30, 202624 min
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
Jul 29, 202617 min
Nordic biotech’s next act: From fragmentation to global force
Jul 23, 202620 min
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
Jul 22, 202621 min
The future of pain relief: Exploring opioid alternatives
Jul 16, 202619 min
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Jul 15, 202621 min
Bonus: Q2 2026 Job Market Update
Jul 14, 20269 min
From sequence to scale: Gene editing’s new era in biologics manufacturing
Jul 10, 202620 min
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
Jul 8, 202617 min
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
Jul 1, 202622 min
The Golden Triangle and the gaps: Rethinking UK biotech
Jun 25, 202619 min
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
Jun 24, 202621 min
From fragile skin to living medicine: Lessons from RDEB
Jun 18, 202621 min
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Jun 17, 202625 min
Portugal, Spain and the new biotech frontier
Jun 10, 202620 min
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Jun 10, 202625 min
Rethinking hair loss treatment
Jun 3, 202621 min
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
Jun 3, 202627 min
France’s biotech ecosystem: science, capital and scale
May 28, 202621 min
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
May 27, 202624 min
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 202623 min
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 202626 min
From MSCs to iPSCs: building the cell therapy future
May 14, 202620 min
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
May 13, 202615 min
Fibrosis, IPF and the search for better therapies
May 7, 202618 min
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
May 6, 202622 min
What makes life science angel investment work?
Apr 30, 202621 min
Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
Apr 29, 202622 min
The next era of diabetes management
Apr 23, 202621 min